LONDON (Alliance News) - Drug discovery and development company Redx Pharma PLC on Thursday said a third paper prepared by The Review on Antimicrobial Resistance, focusing on the need to boost the development of new antibiotic drugs, has been published.
The paper, entitled Securing New Drugs for Future Generations: The Pipeline of Antibiotics, sets out key proposals of ensuring that research and development of antibiotics is commercially sustainable, creating a more stable commercial end market for antibiotics and to reduce barriers to drug development by lowering costs, improving the efficiency of research and lowering global regulatory barriers.
Redx said the report notes that there is a "mismatch" between the increasing resistance to antibiotics and the lack of compounds currently being developed to combat antimicrobial resistant (AMR) bacteria. Redx's Anti-Infectives division is working to create such compounds, it said.
"As the review has highlighted, AMR is one of the critical issues facing global public health today, and it is only by addressing the fundamental challenges unique to antibiotic drug development that we have any chance of tackling this crisis. Redx's innovative partnership with the NHS is just one way that we are working to find solutions to the problem of AMR. We fully support the bold interventions proposed by the review," Chief Executive Neil Murray said in a statement.
Shares in Redx were trading up 1.6% at 89.38 pence Thursday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
